Orziloben
Intestinal Failure-Associated Liver Disease (IFALD)
Phase 2Active
Key Facts
Indication
Intestinal Failure-Associated Liver Disease (IFALD)
Phase
Phase 2
Status
Active
Company
About NorthSea Therapeutics
NorthSea Therapeutics is a private, late-stage biotech advancing a platform of Structurally Engineered Fatty Acids (SEFAs) designed to overcome the limitations of natural fatty acids as drugs. Its lead assets include Icosabutate (Phase 3 for MASH), Orziloben (Phase 2 for IFALD), and SEFA-1024 (Phase 2 for severe hypertriglyceridemia). The company is positioned in large, underserved markets with a differentiated oral therapeutic approach targeting key liver and metabolic pathways.
View full company profileOther Intestinal Failure-Associated Liver Disease (IFALD) Drugs
| Drug | Company | Phase |
|---|---|---|
| IV Choline Chloride | Protara Therapeutics | Phase 2 |